Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Dec;230(6):776-82; discussion 782-4.
doi: 10.1097/00000658-199912000-00006.

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

Affiliations
Clinical Trial

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

J H Klinkenbijl et al. Ann Surg. 1999 Dec.

Abstract

Objective: The survival benefit of adjuvant radiotherapy and 5-fluorouracil versus observation alone after surgery was investigated in patients with pancreatic head and periampullary cancers.

Summary background data: A previous study of adjuvant radiotherapy and chemotherapy in these cancers by the Gastrointestinal Tract Cancer Cooperative Group of EORTC has been followed by other studies with conflicting results.

Methods: Eligible patients with T1-2N0-1aM0 pancreatic head or T1-3N0-1aM0 periampullary cancer and histologically proven adenocarcinoma were randomized after resection.

Results: Between 1987 and 1995, 218 patients were randomized (108 patients in the observation group, 110 patients in the treatment group). Eleven patients were ineligible (five in the observation group and six in the treatment group). Baseline characteristics were comparable between the two groups. One hundred fourteen patients (55%) had pancreatic cancer (54 in the observation group and 60 in the treatment group). In the treatment arm, 21 patients (20%) received no treatment because of postoperative complications or patient refusal. In the treatment group, only minor toxicity was observed. The median duration of survival was 19.0 months for the observation group and 24.5 months in the treatment group (log-rank, p = 0.208). The 2-year survival estimates were 41% and 51 %, respectively. The results when stratifying for tumor location showed a 2-year survival rate of 26% in the observation group and 34% in the treatment group (log-rank, p = 0.099) in pancreatic head cancer; in periampullary cancer, the 2-year survival rate was 63% in the observation group and 67% in the treatment group (log-rank, p = 0.737). No reduction of locoregional recurrence rates was apparent in the groups.

Conclusions: Adjuvant radiotherapy in combination with 5-fluorouracil is safe and well tolerated. However, the benefit in this study was small; routine use of adjuvant chemoradiotherapy is not warranted as standard treatment in cancer of the head of the pancreas or periampullary region.

PubMed Disclaimer

Figures

None
Figure 1. Duration of survival in all eligible patients.
None
Figure 2. Duration of survival in eligible patients with pancreatic head cancer.
None
Figure 3. Duration of survival in eligible patients with periampullary cancer.

Comment in

Similar articles

Cited by

References

    1. Parker SL, Tony T, Bolden S, Wingo PA. Cancer Statistics, 1997. CA Cancer J Clin 1997; 47: 5–27. - PubMed
    1. Trede M. Survival after pancreatoduodenectomy; 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447–458. - PMC - PubMed
    1. Trede M. The surgical treatment of pancreatic carcinoma. Surgery 1985; 97: 28–35. - PubMed
    1. Klinkenbijl JHG, Jeekel J, Schmitz PIM, et al. Carcinoma of the pancreas and periampullary region: palliation versus cure. Br J Surg 1993; 80: 1575–1578. - PubMed
    1. Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996; 78 (3 Suppl): 580–591. - PubMed

Publication types

MeSH terms

Substances